Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to $38.0 million.

  • Arcturus Therapeutics Holdings' Share-based Compensation fell 39.65% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year decrease of 27.09%. This contributed to the annual value of $38.0 million for FY2024, which is 9.64% up from last year.
  • As of FY2024, Arcturus Therapeutics Holdings' Share-based Compensation stood at $38.0 million, which was up 9.64% from $34.6 million recorded in FY2023.
  • In the past 5 years, Arcturus Therapeutics Holdings' Share-based Compensation ranged from a high of $38.0 million in FY2024 and a low of $6.8 million during FY2020.
  • For the 3-year period, Arcturus Therapeutics Holdings' Share-based Compensation averaged around $34.4 million, with its median value being $34.6 million (2023).
  • Data for Arcturus Therapeutics Holdings' Share-based Compensation shows a peak YoY spiked of 327.48% (in 2021) over the last 5 years.
  • Arcturus Therapeutics Holdings' Share-based Compensation (Yearly) stood at $6.8 million in 2020, then spiked by 327.48% to $28.9 million in 2021, then rose by 5.87% to $30.6 million in 2022, then climbed by 13.19% to $34.6 million in 2023, then grew by 9.64% to $38.0 million in 2024.